Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer

• Published in: Oncogene Vol. 43; no. 11; pp. 789 - 803
• Main Authors: Chao, Yapeng, Chen, Yuzhou, Zheng, Wenxiao, Demanelis, Kathryn, Liu, Yu, Connelly, Jaclyn A, Wang, Hong, Li, Song, Wang, Qiming Jane
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 07.03.2024
• Subjects: Animals; Antitumor activity; Castration; Cell cycle; Cell Cycle Proteins - genetics; Cell Line, Tumor; CHK1 protein; Clinical trials; DNA Damage; Humans; Male; Metastases; Mice; Nuclear Proteins - metabolism; Prostate cancer; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - genetics; Protein-Tyrosine Kinases - genetics; Pyrimidinones - pharmacology; Spheroids; Transgenic mice; Tumor cell lines; Tumors
• ISSN: 0950-9232; 1476-5594; 1476-5594
• DOI: 10.1038/s41388-024-02939-z

WEE1 and CHEK1 (CHK1) kinases are critical regulators of the G2/M cell cycle checkpoint and DNA damage response pathways. The WEE1 inhibitor AZD1775 and the CHK1 inhibitor SRA737 are in clinical trials for various cancers, but have not been thoroughly examined in prostate cancer, particularly castration-resistant (CRPC) and neuroendocrine prostate cancers (NEPC). Our data demonstrated elevated WEE1 and CHK1 expressions in CRPC and NEPC cell lines and patient samples. AZD1775 resulted in rapid and potent cell killing with comparable IC50s across different prostate cancer cell lines, while SRA737 displayed time-dependent progressive cell killing with 10- to 20-fold differences in IC50s. Notably, their combination synergistically reduced the viability of all CRPC cell lines and tumor spheroids in a concentration- and time-dependent manner. Importantly, in a transgenic mouse model of NEPC, both agents alone or in combination suppressed tumor growth, improved overall survival, and reduced the incidence of distant metastases, with SRA737 exhibiting remarkable single agent anticancer activity. Mechanistically, SRA737 synergized with AZD1775 by blocking AZD1775-induced feedback activation of CHK1 in prostate cancer cells, resulting in increased mitotic entry and accumulation of DNA damage. In summary, this preclinical study shows that CHK1 inhibitor SRA737 alone and its combination with AZD1775 offer potential effective treatments for CRPC and NEPC.